Gadolinium contrast agent is of limited value for magnetic resonance imaging assessment of synovial hypertrophy in hemophiliacs

Lundin, B.; Berntorp, E.; Pettersson, H.; Wirestam, R.; Jonsson, K.; Ståhlberg, F.; Ljung, R.; Ståhlberg, F
June 2007
Acta Radiologica;Jun2007, Vol. 48 Issue 5, p520
Academic Journal
journal article
Purpose: To examine the influence of different doses of gadolinium contrast agent on synovial enhancement, to compare magnetic resonance imaging (MRI) findings of synovial hypertrophy and radiographic joint changes in hemophiliacs, and to investigate the value of gadolinium in MRI assessment of synovial hypertrophy in hemophiliacs using dynamic MRI and MRI scoring. Material and Methods: Twenty-one hemophiliacs on prophylactic factor treatment without recent bleeds were subjected to radiography and gadolinium contrast-enhanced dynamic and static MRI of the knee using a standard dose of 0.1 mmol/kg b.w. gadoteridol. In 17 of the patients, the MRI procedure was repeated after a triple dose of gadoteridol. Results: MRI findings of synovial hypertrophy were significantly correlated with Pettersson radiographic scores. In 19 of the 21 MRI investigated joints, administration of contrast agent did not alter the result of the evaluation of synovial hypertrophy. Conclusion: The optimal time interval for volume assessment of synovial hypertrophy after injection of gadolinium contrast agent is dose dependent. Hemophiliacs without recent bleeds have minor to abundant synovial hypertrophy in joints with pronounced radiographic changes. Dynamic MRI is not useful for evaluating hemophilic arthropathy, and gadolinium contrast agent is not routinely indicated for MRI scoring of joints in hemophiliacs.


Related Articles

  • Prophylaxis with Recombinant Activated Factor VII in Hemophilia Patients with Inhibitors. Auerswald, Günter; Morfini, Massimo // Journal of Coagulation Disorders;2010, Vol. 2 Issue 1, p1 

    Treatment of bleeding episodes or during surgery in people with hemophilia A (FVIII deficiency) or hemophilia B (FIX deficiency) who have developed antibodies (inhibitors) to FVIII or FIX (especially high titer inhibitors) is difficult as a normal replacement with factor VIII or IX is not...

  • Factors VIII and IX concentrates.  // WHO Technical Report Series;2005, Issue 933, p15 

    The article presents a summary of World Health Organization (WHO) Expert Committee's considerations and justifications for retaining factors VIII and IX concentrates on the WHO Model List of Essential Medicines. The Committee has recommended the retention of factors VIII and IX concentrates...

  • The effects of vitamin C on vitamin K-related clotting factors. Khoshvaghti, Ameneh; Nazifi, S.; Akbarpour, B.; Razavi, S. // Comparative Clinical Pathology;Oct2011, Vol. 20 Issue 5, p513 

    The aim of this study was to assess the effects of vitamin C on vitamin K-related clotting factors II, VII, IX and X. Sixty female Wistar rats with a mean weight of 180 ± 20 g were selected, and after a 5-day adaptation period, control blood samples were taken under anaesthesia. The animals...

  • Central Venous Access Devices (CVAD) for Pediatric Patients with Hemophilia: A Review. Kumar, Riten; Pruthi, Rajiv K.; Rodriguez, Vilmarie // Journal of Coagulation Disorders;2010, Vol. 2 Issue 2, p85 

    Hemophilia A and B are X-linked recessive bleeding disorders caused by deficiencies of blood coagulation factors VIII and IX, respectively. Management of hemophilia essentially entails the use of replacement factors which can be used on demand or on a prophylactic basis. Venous access is...

  • Immunology: Oral solutions. Dolgin, Elie // Nature;11/27/2014 Supplement, Vol. 515 Issue s7528, pS166 

    The article focusses on treatment for haemophilia using bio-engineered oral pills from lettuce leaves to prevent inhibitor formation. Research by researchers Henry Daniell at the University Of Pennsylvania, Philadelphia, and David Lillicrap, of Queen's University in Kingston, Ontario, Canada,...

  • Gene therapy: Genie in a vector. Gould, Julie // Nature;11/27/2014 Supplement, Vol. 515 Issue s7528, pS160 

    The article discusses challenges faced by researchers trying to repair faulty genes causing haemophilia especially in children. Treatments include the infusion of a functional factor IX gene along with DNA to control clotting factor, and a form of gene therapy called genome editing. Research by...

  • Hemofilia. Amador-Medina, Lauro Fabián; Vargas-Ruiz, Ángel Gabriel // Revista Medica del IMSS;nov/dic2013, Vol. 51 Issue 6, p638 

    Hemophilia is a genetic disease in which the clinical manifestation is mainly the presence of hemorrhage. There are two known types of hemophilia: hemophilia A and B, which have a deficiency of factor VIII or IX clotting, respectively. The intensity of bleeding in hemophilia depends on the...

  • The clot thickens for long-lasting drugs that stop hemophilia short. Opar, Alisa // Nature Medicine;Feb2013, Vol. 19 Issue 2, p121 

    The article focuses on the importance of using long-lasting drugs for treatment of hemophilia A and B. It discusses the approval of blood coagulation factor VIII and factor IX. It highlights the interest of various companies in the development of longer-lasting drugs including Biogen Idec Inc.,...

  • BIOGEN AND SOBI PARTNER IN STUDY.  // Worldwide Biotech;Jan2014, Vol. 26 Issue 1, p2 

    The article reports on the results of the Phase 3 trials of recombinant factor IX- and VIII-Fc fusion protein candidates from biotechnology company Biogen Idec Inc. and healthcare company Swedish Orphan Biovitrum AB in the U.S. The prolonged half-lives of the recombinant clotting factors are...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics